• Pancreatic, thyroid, and other endocrine cancers

Zanosar Generic Name & Formulations

General Description

Streptozocin 1g/vial; pwd for IV inj or infusion after reconstitution/dilution; preservative-free.

Pharmacological Class


How Supplied

Single-use vial—1


Zanosar Indications


Symptomatic or progressive metastatic pancreatic islet cell cancer.

Zanosar Dosage and Administration


1g/m2 IV once weekly for 2 weeks; may repeat weekly; max 1.5g/m2 per dose. Or, 500mg/m2 IV daily for 5 days every 6 weeks until max benefit or toxicity.


Not recommended.

Zanosar Contraindications

Not Applicable

Zanosar Boxed Warnings

Boxed Warning

Should be administered under the supervision of an experienced physician. Have access to a facility with laboratory and supportive resources sufficient to monitor drug tolerance and toxicity. Mutagenic, tumorigenic, or carcinogenic.

Zanosar Warnings/Precautions


Renal dysfunction or disease. Monitor renal function (eg, urinalysis, BUN, creatinine, electrolytes) before, weekly during, and for 4 weeks after therapy; discontinue or reduce dose if significant renal toxicity occurs (see full labeling). Obtain CBCs, liver function tests weekly. Avoid extravasation. Ensure adequate hydration. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.

Zanosar Pharmacokinetics

See Literature

Zanosar Interactions


Avoid concomitant nephrotoxic agents. Additive toxicity with other cytotoxic drugs. Severe bone marrow toxicity with doxorubicin. Phenytoin may reduce cytotoxicity.

Zanosar Adverse Reactions

Adverse Reactions

GI upset (may be severe); hematological, hepatic and renal (cumulative and dose-related; may be fatal) toxicity; glucose intolerance, nephrogenic diabetes insipidus, inj site reactions, CNS effects (eg, confusion, lethargy, depression).

Zanosar Clinical Trials

See Literature

Zanosar Note

Not Applicable

Zanosar Patient Counseling

See Literature